10 Small–Cap Stocks Insiders Are Selling Recently

5. Bicycle Therapeutics plc (NASDAQ:BCYC)

Number of insiders selling: 8

Market capitalization: $870.67M

In the middle of this list of 10 small-cap stocks insiders are selling recently is Bicycle Therapeutics, a clinical-stage biopharmaceutical company, focused on the development of a class of medicine for undeserved diseases in the US and the UK.

The company’s proprietary Bicycle platform technology develops novel peptide-based therapeutics for oncology treatment. The company’s goal is to become the leader in solid tumor medicine by the number of patients able to treat. Bicycle Therapeutics develops a class of medicines called Bicycles, which are chemically synthesized peptides constrained to form two loops. These structures demonstrate high stability and affinity for targets, translating into therapies having favorable efficacy and safety profiles.

The company’s leading candidate zelenectide pevedotin (formerly BT8009), has been positioned as a potential alternative to existing treatments like Padcev for patients with metastatic urothelial carcinoma (mUC). While the company is primarily focused on oncology treatments, its Bicycle platform shows huge potential for expansion into other therapeutic areas.

In its latest update on the leading candidate, the company revealed that new data continue to position zelenectide pevedotin as a potentially promising best-in-class therapy for mUC.

In January, eight insiders, among which is the company’s CEO, sold a total of around $548,178 worth of shares, at an average price of $14.41. The stock is currently trading $12.49 having lost 10.79% since the beginning of the year. Over the last five years, its shares declined 16.34%.

As many as nine analysts have an average “Buy” rating on the stock, and the 12-month price target is $33.25. This represents an increase of 166.21% from the latest price, as per data from StockAnalysis.

Bicycle Therapeutics is also one of the 10 Top Performing European Stocks Heading into 2025.